Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

ASCO 2018: Dr. Birrer on Practice-Changing Ovarian Cancer Studies

June 2nd 2018

ASCO 2018: Dr. Bekaii-Saab Highlights Pancreatic Cancer Abstracts

June 2nd 2018

ASCO 2018: Dr. Coleman Shares Insight on Ongoing Research in Ovarian Cancer

June 2nd 2018

ASCO 2018: Dr. Weber Highlights Exciting Abstracts in Melanoma

June 2nd 2018

ASCO 2018: Dr. Lonial Highlights CAR T-Cell Therapy and More in Myeloma

June 2nd 2018

ASCO 2018: Dr. Burris Highlights TAILORx and More in Breast Cancer

June 2nd 2018

ASCO 2018: Dr. Esteva Highlights CDK4/6 Inhibitors and More in Breast Cancer

June 2nd 2018

ASCO 2018: Dr. Borghaei Highlights Immunotherapy Findings in Lung Cancer

June 2nd 2018

Practice Changes for Use of Immunotherapy in NSCLC

June 2nd 2018

OncLive News Network On Location: In Chicago Monday, June 4

June 2nd 2018

OncLive News Network On Location: In Chicago Sunday, June 3

June 2nd 2018

OncLive News Network On Location: In Chicago Saturday, June 2

June 2nd 2018

OncLive News Network On Location: In Chicago Friday, June 1

June 2nd 2018

Expert Explains Evolving Role of Radiotherapy in NSCLC

May 31st 2018

James Urbanic, MD, discusses the evolving role of radiotherapy in patients with oligometastatic and metastatic non–small cell lung cancer.

ASCO 2018: Top Oncologists Select Key, Practice-Changing Abstracts

May 30th 2018

Key opinion leaders spoke with OncLive ahead of the 2018 ASCO Annual Meeting to share the top abstracts they believe could have the greatest impact on clinical practice and patient outcomes across lymphomas, gastrointestinal cancers, genitourinary cancers, and lung cancer.

FDA Grants Crizotinib Breakthrough Designation for MET+ NSCLC and ALK+ ALCL

May 30th 2018

The FDA has granted crizotinib a breakthrough therapy designation for the treatment of patients with metastatic non–small cell lung cancer with MET exon 14 alterations, and for use in patients with relapsed/refractory ALK+ anaplastic large cell lymphoma.

Studies Stopped for Daratumumab/Checkpoint Inhibitor Combos in NSCLC, Myeloma

May 29th 2018

Two separate early-phase clinical trials exploring daratumumab in combination with either a PD-1 inhibitor for multiple myeloma or a PD-L1 inhibitor for non–small cell lung cancer were terminated following a planned interim analysis.

Atezolizumab Plus Carboplatin/Nab-Paclitaxel Improves OS in Frontline NSCLC

May 29th 2018

Adding atezolizumab (Tecentriq) to nab-paclitaxel (Abraxane) and carboplatin in the frontline setting significantly improved overall survival in patients with advanced non–small cell lung cancer.

Patel Provides Perspective on Immunotherapy Developments in NSCLC

May 25th 2018

Sandip P. Patel, MD, discusses existing and emerging immunotherapy approaches for patients with locally advanced and metastatic NSCLC.

Durvalumab Improves Survival in Stage III NSCLC

May 25th 2018

Durvalumab significantly improved overall survival versus placebo when used as a sequential treatment in patients with locally-advanced, unresectable non–small cell lung cancer who had not progressed following standard chemoradiotherapy, according to updated findings from the phase III PACIFIC trial.